Cosmos Health C-Sept PRO sales exceed $1.3 million at 72% margin
Cosmos Health Inc. reported that its C-Sept PRO antiseptic solution is on track for annualized sales exceeding $1.3 million with a 72% gross margin, driven by adoption in Greek hospitals. Average monthly sales accelerated from over $93,000 in the last six months to more than $108,000 in the last three months. The company plans to expand this high-margin hospital business into other European markets.
*this image is generated using AI for illustrative purposes only.
Cosmos Health Inc. announced that its proprietary antiseptic solution, C-Sept PRO, has gained significant traction across leading public and private hospital groups in Greece, positioning the product as a key high-margin revenue driver. The company reported that C-Sept PRO is on track to achieve annualized sales exceeding $1.3 million, supported by a gross margin of approximately 72%. This performance underscores the product's growing acceptance and the strength of the company's infection-control portfolio in the hospital channel.
Sales Momentum and Financial Metrics
The sales trajectory for C-Sept PRO has shown consistent acceleration over the past six months. Average monthly sales exceeded $93,000 during this period, rising to more than $108,000 per month over the last three months. This growth is driven by adoption across major Greek hospital groups and a consistent pattern of repeat ordering. The company projects that this momentum will result in annualized gross profit of approximately $0.9 million.
| Metric | Value |
|---|---|
| Average monthly sales (last 6 months) | > $93,000 |
| Average monthly sales (last 3 months) | > $108,000 |
| Projected annualized sales | > $1.3 million |
| Projected annualized gross profit | ~ $0.9 million |
| Gross margin | ~ 72% |
Product Profile and Market Application
C-Sept PRO is a professional-grade antiseptic alcohol solution that combines 2% w/v chlorhexidine gluconate with 76% w/v isopropyl alcohol. The solution is fast-acting within one minute and offers wide-spectrum activity against gram-positive and gram-negative bacteria, viruses, and fungi. The alcohol component delivers rapid initial action, while chlorhexidine provides prolonged activity on the skin, even in the presence of biological fluids.
In hospital settings, C-Sept PRO is indicated for surgical and daily hand disinfection, pre-operative skin disinfection, skin preparation for injections and venipunctures, and skin disinfection prior to vascular catheterization. The product is available in formats ranging from 250 ml to 20 L to accommodate various clinical needs.
Strategic Outlook and Expansion
Cosmos Health views its hospital business as a new, high-margin revenue generator that combines attractive economics with revenue visibility due to recurring demand. The company intends to leverage Cana Laboratories' European GMP-certified manufacturing platform and its established distribution footprint to extend the hospital-focused antiseptics business into additional European markets over time.
Greg Siokas, CEO of Cosmos Health, stated that the accelerating momentum demonstrates the strength of the company's proprietary antiseptics franchise. He highlighted the opportunity to scale further across Greece and expand the hospital business into other European markets, citing the product's strong recurring demand and high margins.
What specific European markets is Cosmos Health targeting for the initial expansion of the C-Sept PRO hospital business?
What is the expected timeline for launching the product in these new international markets?
How does the company plan to scale production at Cana Laboratories to meet potential increases in European demand?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
